Blog

Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...

  Executive summary Highlight 1: Increased presence of multinational corporations in newly listed products from the 2022 NRDL negotiations The 2022 NRDL negotiations finished immediately before the week-long Chinese New Year holidays in January 2023, adding 83 novel non-traditional Chinese medicines...

  Meet Melissa Leonhauser: Melissa has over 20 years of experience managing analytic solutions that support pharmaceutical brand teams. She has helped introduce and shape how pharmaceutical manufacturers use Real World Data to understand the patient journey and inform their decision...

  Executive Summary:   Introduction & History of the Regular Price Revisions in Japan  For over two decades, Japan has maintained a biennial re-pricing approach in which drug prices are surveyed through wholesaler offices and healthcare institutions to capture the product discrepancy...

  Last month, Trinity attended the ISPOR Europe 2022 conference in Vienna. The main theme of the conference was “Collaborating Across Borders: Building & Using Evidence to Enable Access”, which facilitated many interesting discussions amongst different stakeholders in life sciences, including...

  Executive Summary Introduction The OCM has recently concluded after five years of existence. Institutional participants advocated for a follow-up model – and following numerous reviews and analyses of the successes and points of improvement of the OCM, Centers for Medicare...